Single Biggest Cancer Dictionary in the World
What is anti-EGFR antibody-drug conjugate CPO301?
Pronunciation: /ˈænˌti egfr* ˈæntɪˌbɑdi drəg ˌkɑnʤəˈgeɪt cpo* θri ˈhənərd ənd wən/
anti-EGFR antibody-drug conjugate CPO301
Definition
An antibody-drug conjugate (ADC) consisting of a monoclonal antibody directed against the epidermal growth factor receptor (EGFR; HER1; ErbB1) linked to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon administration of anti-EGFR ADC CPO301, the monoclonal antibody moiety binds to EGFR on tumor cell surfaces. Upon binding and internalization, the cytotoxic agent is released and kills the EGFR-expressing cancer cells, through an as of yet unknown mechanism of action. EGFR, overexpressed by a variety of cancers, plays a key role in tumor cell proliferation and survival.